AstraZeneca Moves To Fend Off Generic Seroquel

Law360, New York (February 8, 2008, 12:00 AM EST) -- In an attempt to stave off the launch of a generic copy of its top-selling anti-psychotic drug Seroquel, AstraZeneca Pharmaceuticals LP has asked a federal court for permission to file a summary judgment motion in its spat with generics drugmaker Teva Pharmaceutical USA Inc.

In a letter filed Wednesday with U.S. District Court for the District of New Jersey, lawyers for AstraZeneca said the proposed motion was necessary given the “imminent expiration” of the 30-month regulatory freeze on the launch of Teva's version of the pill....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.